Beryl Drugs reappoints key directors, adopts financials at AGM

Beryl Drugs Limited held its 32nd Annual General Meeting (AGM) on September 30, 2025. Shareholders reappointed Sudhir Sethi as a director and Sanjay Sethi as managing director for a further five-year term, effective December 11, 2025. Sanjay Sethi, 62, holds a B. Pharma degree and has 43 years of experience.

The AGM also approved the appointment of Dipika Kataria as secretarial auditor for a five-year term, concluding with the 37th AGM in 2030. Shareholders adopted the audited financial statements for the fiscal year ended March 31, 2025, including the balance sheet, statement of profit & loss, and cash flow, along with reports from the board of directors and auditors.

The meeting, chaired by Sudhir Sethi, confirmed the presence of 45 members, satisfying the quorum requirement against a total of 7,501 eligible members as of September 23, 2025. All resolutions were passed by requisite majorities, with the company utilizing remote e-voting and poll facilities.